Feasibility, safety, and efficacy of ultrasound-induced nuclear resonance therapy for glioblastoma: an exploratory phase 1 study

A study investigating the feasibility, safety, and efficacy of using low-intensity non-focused ultrasound-stimulated nuclear resonance therapy for the treatment of glioblastoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500100888

Enrollment

Unknown

Registered

2025-04-16

Start date

2025-05-01

Completion date

Unknown

Last updated

2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

Ultrasound intervention group:Concomitant with or following standard radiotherapy and chemotherapy post-surgery, the treatment with low-intensity non-focused ultrasound at the sensitive frequency is a

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-70 years old (inclusive of 18 and 70). (2) Able to undergo surgical treatment, with postoperative pathology confirmed as glioblastoma. (3) Karnofsky Performance Status score >= 70 within 14 days postoperatively. (4) Patients receive standard radiotherapy and chemotherapy after surgery. (5) Willing to sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with tumors in other parts of the body. (2) Patients with severe other systemic diseases, such as various heart diseases leading to left ventricular ejection fraction (LVEF) <= 45%, glomerular filtration rate <= 30 mL/min, or serum creatinine level <= 450 µmol/L, etc. (3) Patients with recurrent tumors who have previously undergone surgery or other treatments. (4) The presence of multiple glioblastoma lesions within the intracranial region.

Design outcomes

Primary

Measure	Time frame
Treatment-related adverse events;	—

Secondary

Measure	Time frame
Rate of detecting sensitive frequencies;Survival status of the patient at 6 months and 12 months postoperatively;The progression of the tumor at 6 months and 12 months postoperatively compared to the status before the treatment with low-intensity non-focused ultrasound (within 1 month before treatment);The progression of the tumor at 6 months and 12 months postoperatively compared to its status in the early;The overall survival of the patients, and the survival rates at 6 months and 12 months postoperatively;The progression-free survival of the patients, and the progression-free survival rates at 6 months and 12 months postoperatively;	—

Measure

Time frame

Rate of detecting sensitive frequencies;Survival status of the patient at 6 months and 12 months postoperatively;The progression of the tumor at 6 months and 12 months postoperatively compared to the status before the treatment with low-intensity non-focused ultrasound (within 1 month before treatment);The progression of the tumor at 6 months and 12 months postoperatively compared to its status in the early;The overall survival of the patients, and the survival rates at 6 months and 12 months postoperatively;The progression-free survival of the patients, and the progression-free survival rates at 6 months and 12 months postoperatively;

—

Countries

China

Contacts

Public ContactChiyuan Ma

Department of Neurosurgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

machiyuan_nju@126.com+86 134 0193 1231

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026